嵌合抗原受体基因修饰T（chimeric antigen receptor gene-modified T，CAR-T）细胞治疗技术自从2010年以来在临床上不断取得突破，特别是靶向CD19 分子在针对难治、复发的B细胞来源的血液肿瘤（急、慢性淋巴细胞白血病，非霍奇金淋巴瘤）的治疗上，获得了传统疗法无法达到的临床疗效，成为当下肿瘤免疫治疗中最为引人关注的领域。不过CAR-T细胞技术在治疗中不断出现的高复发率、毒副作用及CAR-T细胞高昂的制备成本都为这一技术的产业化前景带来了不确定性。本文总结了目前国际上CAR-T细胞治疗技术领军企业的发展现状，就该技术产业化发展面临的挑战进行了深入分析，并展望该产业的发展趋势和产业化前景。

The chimeric antigen receptor gene-modified T cells (CAR-T) technique has constantly made breakthroughs in clinical practice since 2010, especially in the treatment of refractory, relapsed B cell-derived hematologic malignancies (such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma), targeting CD19 molecule of the CAR-T has obtained clinical efficacy which has never been achieved by traditional tumor therapy strategies, and become the most attractive area of the moment in cancer immunotherapy. However, high recurrence rate, toxic side effects and expensive preparation costs of CAR-T, which appeared constantly in the CAR-T cell therapy, have also brought uncertainties to the industrialization of this technique. The article summarized the current development situation of CAR-T cell therapy technique in leading enterprises of the world and thoroughly analyzed challenges to the development of this technique industrialization, as well as evaluated development trend and industrialization prospect of this technique.

血液学协同创新中心资助项目（No. XYXT2015304）；山东省重点研发计划资助项目（No. 2015GSF118108）